Australian and New Zealand children now have access to the latest brain cancer trial for DIPG.
ANZCHOG is pleased to announce that the latest European clinical trial for Diffuse Intrinsic Pontine Glioma (DIPG), one of the deadliest forms of paediatric brain cancer, is now available for Australian children. The BIOMEDE (Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication) trial has been developed by leading international paediatric oncology trial researchers within the European trial consortium "Innovative Therapies in Children with Cancer (ITCC)”.
Access to this trial has been made possible by support from Cure Brain Cancer Foundation and the Isabella & Marcus Foundation, with additional support from Navzad Memorial Foundation.
BIOMEDE is currently available at Children's Hospital at Westmead, and will be opened at all Australian and New Zealand children's cancer centres that treat DIPG.
Further information about the BIOMEDE trial can be found in the media release